Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CUE 
Cue Biopharma (CUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CUE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.88% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.59M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 4 | Beta 1.53 | 52 Weeks Range 0.45 - 1.99 | Updated Date 08/28/2025 |
52 Weeks Range 0.45 - 1.99 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.14 | Actual -0.09 |
Profitability
Profit Margin - | Operating Margin (TTM) -292.32% |
Management Effectiveness
Return on Assets (TTM) -59.43% | Return on Equity (TTM) -195.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 43585978 | Price to Sales(TTM) 7.43 |
Enterprise Value 43585978 | Price to Sales(TTM) 7.43 | ||
Enterprise Value to Revenue 5.26 | Enterprise Value to EBITDA -1.76 | Shares Outstanding 76845904 | Shares Floating 76580017 |
Shares Outstanding 76845904 | Shares Floating 76580017 | ||
Percent Insiders 0.35 | Percent Institutions 22.62 |
Upturn AI SWOT
Cue Biopharma
Company Overview
History and Background
Cue Biopharma, founded in 2011, is a clinical-stage biopharmaceutical company focused on developing a novel class of biologics called Immuno-STATs (Selective Targeting and Activation Reagents) designed to selectively engage and modulate the human immune system to fight cancer and autoimmune diseases. It was formerly known as ImmuLogic Pharma.
Core Business Areas
- Immuno-STAT Biologics: Development of Immuno-STAT biologics for cancer immunotherapy and autoimmune diseases. The platform is designed to precisely target and activate specific T cells to elicit a therapeutic immune response.
Leadership and Structure
Cue Biopharma's leadership team includes experienced professionals in drug development and commercialization. The organizational structure is typical of a biotechnology company, with departments focused on research and development, clinical trials, manufacturing, and business development.
Top Products and Market Share
Key Offerings
- CUE-101: Lead clinical candidate, CUE-101, is an IL-2 based Immuno-STAT designed to target and activate tumor-specific T cells expressing the NY-ESO-1 antigen, commonly found in various cancers. Currently in clinical trials for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Market share and revenue data is not publicly available as it is still in clinical development. Competitors in the HNSCC space include Merck (KEYTRUDA), Bristol-Myers Squibb (Opdivo), and other companies developing targeted therapies and immunotherapies.
- CUE-102: CUE-102, targeting WT1, is also in development. Revenue and market share data are not yet available as it's still in clinical trials. Competitors include companies developing WT1-targeted therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investments in research and development. Immuno-oncology, the area where Cue Biopharma operates, is experiencing substantial growth due to the success of checkpoint inhibitors and other immunotherapies.
Positioning
Cue Biopharma aims to differentiate itself through its Immuno-STAT platform, which seeks to offer more precise and targeted immune activation compared to traditional approaches like checkpoint inhibitors. This targeted approach seeks to improve efficacy and reduce toxicity.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions USD. Cue Biopharma's positioning within this TAM depends on the clinical success and commercialization of its Immuno-STAT candidates.
Upturn SWOT Analysis
Strengths
- Novel Immuno-STAT technology platform
- Targeted T-cell activation
- Potential for improved efficacy and reduced toxicity
- Clinical-stage pipeline
Weaknesses
- Clinical-stage company with no products on the market
- Reliance on Immuno-STAT platform success
- Limited financial resources relative to larger competitors
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of Immuno-STAT platform to other therapeutic areas
- Positive clinical trial results
- Orphan drug designation for specific indications
Threats
- Competition from established immunotherapy players
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
- Economic downturn impacting funding for biotechnology companies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- NVS
Competitive Landscape
Cue Biopharma's competitive advantage lies in its Immuno-STAT technology, which offers a targeted approach to T-cell activation. However, it faces competition from larger companies with established immunotherapy products and pipelines.
Growth Trajectory and Initiatives
Historical Growth: Growth is currently driven by advancement in the clinical pipeline, not sales.
Future Projections: Future growth depends heavily on successful clinical trial outcomes, regulatory approvals, and strategic partnerships. Analyst estimates vary widely depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include progressing CUE-101 and CUE-102 through clinical trials and exploring new applications of the Immuno-STAT platform.
Summary
Cue Biopharma is a clinical-stage company with a novel Immuno-STAT platform that has the potential to revolutionize cancer treatment. Its success hinges on positive clinical trial results and its ability to secure partnerships. However, the company faces significant risks, including clinical trial failures, competition, and funding challenges. The stock is highly speculative and should be treated accordingly.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cue Biopharma Investor Relations
- SEC Filings
- Industry Reports
- Analyst Research
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cue Biopharma
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2018-01-02 | CEO, Interim Principal Financial and Accounting Officer & Director Mr. Daniel R. Passeri J.D., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.cuebiopharma.com |
Full time employees 41 | Website https://www.cuebiopharma.com | ||
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.